1. Budiawan H, Salavati A, Kulkarni HR, Baum RP (2014) Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using 90Yttrium and 177Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 4(1): 39–52
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Martin Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer, The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19(11): 1167–1214
3. Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O (2007) Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 3)—AWWF-Registriernummer: 031–002
4. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44(3): 451–652
5. Eiber M, Gärtner F, Scheidhauer K, Souvatzoglo M (2013) Thyroid and Endocrine Tumours. In: Ratib O et al. (Hrsg) Atlas of PET/MR Imaging in Oncology. Springer, Heidelberg, S 197–210